Vertex Pharmaceuticals (VRTX) Other Non Operating Income (2009 - 2026)
Vertex Pharmaceuticals (VRTX) posted quarterly Other Non Operating Income of $6.5 million for Q4 2025, up 143.62% year-over-year from $2.7 million in Q4 2024, and up 166.33% quarter-over-quarter from -$9.8 million in Q3 2025.
Vertex Pharmaceuticals (VRTX) Other Non Operating Income (2009 - 2026) Analysis & Trends
Vertex Pharmaceuticals' Other Non Operating Income history runs 17 years deep, the most recent figure standing at $6.5 million for Q4 2025.
- In Q4 2025, Other Non Operating Income rose 143.62% year-over-year to $6.5 million; the TTM figure through Mar 2026 stood at $9.9 million (up 113.66% YoY), while the FY2025 annual figure was -$7.7 million, up 91.06% from the prior year.
- Other Non Operating Income for Q4 2025 stood at $6.5 million, up from -$9.8 million in the prior quarter.
- The five-year high for Other Non Operating Income was $42.4 million in Q3 2021, with the low at -$78.1 million in Q2 2022.
- The 5-year median for Other Non Operating Income is -$12.4 million (2023), against an average of -$13.8 million.
- The sharpest annual moves came in 2024 and 2025: Other Non Operating Income tumbled 2500.0% in 2024, then jumped 157.14% in 2025.
- Vertex Pharmaceuticals' Other Non Operating Income stood at $7.1 million in 2021, then plunged by 538.03% to -$31.1 million in 2022, then jumped by 68.49% to -$9.8 million in 2023, then tumbled by 52.04% to -$14.9 million in 2024, then jumped by 143.62% to $6.5 million in 2025.
- Business Quant data shows VRTX's Other Non Operating Income at $6.5 million in Q4 2025, -$9.8 million in Q3 2025, and $13.2 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 24.30 Mn |
| Dec 31, 2025 | 6.50 Mn |
| Sep 30, 2025 | -9.80 Mn |
| Jun 30, 2025 | 13.20 Mn |
| Mar 31, 2025 | -17.60 Mn |
| Dec 31, 2024 | -14.90 Mn |
| Sep 30, 2024 | -16.90 Mn |
| Jun 30, 2024 | -23.10 Mn |
| Mar 31, 2024 | -31.20 Mn |
| Dec 31, 2023 | -9.80 Mn |
| Sep 30, 2023 | -15.90 Mn |
| Jun 30, 2023 | 1.60 Mn |
| Mar 31, 2023 | 1.30 Mn |
| Dec 31, 2022 | -31.10 Mn |
| Sep 30, 2022 | 17.20 Mn |
| Jun 30, 2022 | -78.10 Mn |
| Mar 31, 2022 | -72.80 Mn |
| Dec 31, 2021 | 7.10 Mn |
| Sep 30, 2021 | 42.40 Mn |
| Jun 30, 2021 | 8.10 Mn |